ARCHIVES

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

This article is from The Cancer Letter archive.

Vol. 33 No. 46 | December 14, 2007

Download PDF Visit The Full Archive

Related Articles

NIH director; Targets Increases Favor Established Researchers

May 9, 1997

HER2+ Tumors Increase Risk Of Recurrence, Study Finds

November 27, 2009

Hawaii Epidemiology Studies Offer Opportunities For Major Impact On Cancer Incidence, Survival

January 4, 1985

Tempero, Johnson To Lead ASCO

March 28, 2003

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

Gene Therapy Experiments Get RDAC Okay

August 10, 1990